The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO 2026 | Outcomes from a MAIC comparing epcoritamab-R-squared with tafasitamab-R-squared in R/R FL
Kim Linton, MBChB, MRCP, PhD, FRCP, University of Manchester and The Christie NHS Foundation Trust, Manchester, UK, presents results of an anchored matching-adjusted indirect treatment comparison (MAIC) which found epcoritamab plus lenalidomide and rituximab (R-squared) to outperform tafasitamab-R-squared across efficacy outcomes in relapsed/refractory follicular lymphoma (R/R FL). Dr Linton notes that epcoritamab-R-squared is associated with more adverse events, making it a suitable option for patients with higher-risk disease. This interview took place at the 14th Annual Meeting of the Society of Hematologic Oncology (SOHO 2026) in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
